Single-cell sequencing reveals the tumor immune microenvironment in thyroid cancer: a narrow review.
The immune microenvironment profoundly shapes the progression and therapeutic response of thyroid carcinoma.
APA
Liang K, Wang Z, et al. (2025). Single-cell sequencing reveals the tumor immune microenvironment in thyroid cancer: a narrow review.. Frontiers in immunology, 16, 1738583. https://doi.org/10.3389/fimmu.2025.1738583
MLA
Liang K, et al.. "Single-cell sequencing reveals the tumor immune microenvironment in thyroid cancer: a narrow review.." Frontiers in immunology, vol. 16, 2025, pp. 1738583.
PMID
41562080
Abstract
The immune microenvironment profoundly shapes the progression and therapeutic response of thyroid carcinoma. Through comprehensive analysis of single-cell RNA sequencing data, this review delineates the immune landscapes of papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinomas (PDTC), and anaplastic thyroid carcinomas (ATC), revealing a differentiation dependent trajectory of tumor immune microenvironment remodeling-from immune activation suppression coexistence in PTC, to immune exclusion in PDTC, and terminal exhaustion in ATC. This single-cell based approach enables high resolution dissection of cellular heterogeneity, immune crosstalk, and spatial organization that are often masked in bulk analyses. Such insights provide a scientific basis for precision immunotherapy, offering guidance for differentiation tailored strategies to overcome immune escape and improve clinical outcomes in thyroid cancer.
MeSH Terms
Humans; Tumor Microenvironment; Thyroid Neoplasms; Single-Cell Analysis; Animals; Thyroid Cancer, Papillary
같은 제1저자의 인용 많은 논문 (3)
- Integrative deep learning analysis of 2D and 3D body composition features for predicting postoperative pancreatic fistula after distal pancreatectomy.
- "Nasal Valve Tensioning versus Crural Strut Grafts in the Management of External Nasal Valve Dysfunction".
- Association of congenital iodine deficiency syndrome and differentiated thyroid cancer: a Mendelian randomization study.